SC 14D9 1 a10496652a.htm a10496652a.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
SCHEDULE 14D-9
 
 
SOLICITATION/RECOMMENDATION STATEMENT UNDER
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Astex Pharmaceuticals, Inc.
(Name of Subject Company)

Sarissa Capital Domestic Fund LP
Sarissa Capital Offshore Master Fund LP
Sarissa Capital Management LP
Dr. Alexander Denner
Dr. Richard Mulligan
(Name of Persons Filing Statement)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

04624B103
(CUSIP Number of Class of Securities)

Mark DiPaolo, Esq.
General Counsel
Sarissa Capital Management LP
660 Steamboat Road
Greenwich, CT 06830
(203) 302-2330
(Name, address and telephone numbers of person authorized to receive notices
 and communications on behalf of the persons filing statement)
 
 
o
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
 
 
 
 
 
 
TABLE OF CONTENTS
 
 
Item 1.
Subject Company Information.
3
     
Item 2.
Identity and Background of Filing Person.
3
     
Item 3.
Past Contacts, Transactions, Negotiations and Agreements.
3
     
Item 4.
The Solicitation or Recommendation.
3
     
Item 5.
Persons/Assets Retained, Employed, Compensated or Used.
3
     
Item 6.
Interest in Securities of the Subject Company.
4
     
Item 7.
Purposes of the Transaction and Plans or Proposals.
4
     
Item 8.
Additional Information to be Furnished.
5
     
Item 9.
Exhibits.
5

 
- 2 -
 
 
Item 1.   Subject Company Information.
 
Name and Address
 
The name of the subject company is Astex Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Astex”), and the address of the principal executive offices of the Company is 4140 Dublin Blvd, Suite 200, Dublin, California, 94568.  The telephone number for its principal executive offices is (925) 560-0100.
 
Class of Securities
 
The title of the class of equity securities to which this Solicitation/Recommendation Statement on Schedule 14D-9 (together with all Exhibits hereto, this “Schedule 14D-9”) relates is common stock, par value $0.001 per share of the Company (collectively, the “Shares”).  Based solely on information set forth in the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company on September 13, 2013, there were 95,006,917 Shares issued and outstanding as of the close of business on September 12, 2013.
 
Item 2.   Identity and Background of Filing Person.
 
Name and Address of Persons Filing this Statement
 
The name of the filing persons are: (i) Sarissa Capital Domestic Fund LP, a Delaware limited partnership; (ii) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership; (iii) Sarissa Capital Management LP, a Delaware limited partnership; (iv) Dr. Alexander Denner, a citizen of the United States of America; and (v) Dr. Richard Mulligan, a citizen of the United States of America (collectively, the “Filing Persons”).  The business address of each Filing Person is 660 Steamboat Road, Greenwich, CT, 06830.   The business telephone number of each Filing Person is (203) 302-2330.
 
Tender Offer
 
This Schedule 14D-9 relates to the cash tender offer (the “Tender Offer”) by Autumn Acquisition Corporation, a Delaware corporation (“Purchaser”) and wholly owned indirect subsidiary of Otsuka Pharmaceutical Co., Ltd., a joint stock company organized under the laws of Japan (“Parent”), to purchase all of Astex’s outstanding Shares at a price of $8.50 per Share, payable net to the seller in cash without interest thereon, less any applicable withholding taxes (the “Offer Price”), upon the terms and subject to the conditions set forth in Purchaser’s Offer to Purchase dated September 13, 2013 (as amended or supplemented from time to time), and in the related Letter of Transmittal (as amended or supplemented from time to time).  The Tender Offer is described in a Tender Offer Statement on Schedule TO (as amended or supplemented from time to time, the “Schedule TO”), which was filed by Purchaser with the U.S. Securities and Exchange Commission on September 13, 2013.  The Tender Offer is being made pursuant to an Agreement and Plan of Merger, dated as of September 5, 2013 (the “Merger Agreement”), by and among Parent, Purchaser and the Company.
 
The Schedule TO states that the business address and telephone number of Purchaser are 2-9 Kanda, Tsukasa-machi, Chiyoda-ku, Tokyo 101-8535, Japan and +81-3-6717-1400, respectively.
 
Item 3.   Past Contacts, Transactions, Negotiations and Agreements.
 
None.
Item 4.   The Solicitation or Recommendation.
 
Reference is made to the press release dated October 2, 2013, a copy of which is filed as Exhibit 1 hereto and is incorporated herein by reference.

Item 5.   Persons/Assets Retained, Employed, Compensated or Used.
 
Not applicable.
 
 
 
- 3 -
 
 
 
Item 6.   Interest in Securities of the Subject Company.
 
In the 60 days prior to this filing, the following describes the Filing Persons’ purchase and sale activity in the Shares, all of which occurred in the open market:

Sarissa Capital Domestic Fund LP

Date
Shares Purchased
Price Per Share
08/12/2013
36,794
$5.13
08/14/2013
12,077
$5.27
08/15/2013
42,268
$5.12
08/30/2013
146,902
$6.53
09/03/2013
36,298
6.61
09/05/2013
2,332,744
$8.49

Sarissa Capital Offshore Master Fund Ltd
 
Date
Shares Purchased
Price Per Share
08/12/2013
23,206
$5.13
08/14/2013
7,923
$5.27
08/15/2013
27,732
$5.12
08/30/2013
96,380
$6.53
09/03/2013
29,807
$6.61
09/05/2013
1,574,046
$8.49
 
 
Item 7.   Purposes of the Transaction and Plans or Proposals.  
 
Not applicable.
 
Item 8.   Additional Information to be Furnished.
 
Not applicable.
 

 
- 4 -
 
 
Item 9.   Exhibits.  
 
INDEX TO EXHIBITS

Exhibit No.

 
1.
 
  
 
Press Release, dated October 2, 2013
 


 
- 5 -
 

SIGNATURE


After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
SARISSA CAPITAL DOMESTIC FUND LP
     
 
By: Sarissa Capital Fund GP LP, its general partner
     
     
 
By:
 /s/ Seth Platt                    
   
Name:  Seth Platt
   
Title:  Authorized Person
     
     
     
 
SARISSA CAPITAL OFFSHORE MASTER FUND LP
     
 
By: Sarissa Capital Offshore Fund GP LLC, its general partner
     
 
By:
 /s/ Seth Platt               
   
Name:  Seth Platt
   
Title:  Authorized Person
     
     
 
SARISSA CAPITAL MANAGEMENT LP
     
 
By:
/s/ Seth Platt               
   
Name:  Seth Platt
   
Title:  Authorized Person
     
     
 
/s/ Alexander Denner            
 
Name: Alexander Denner
   
   
  /s/ Richard Mulligan               
  Name:  Richard Mulligan 


Dated:  October 8, 2013